Study S001157

A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01652729
Acronym: DURATION-NEO-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 365
Start: 2013-02
Primary completion: 2014-04
Lead sponsor: AstraZeneca
Conditions: Diabetes Type 2
Interventions: DRUG:Exenatide once weekly suspension; DRUG:Sitagliptin; DRUG:Placebo
Results posted: TRUE
Secondary identifiers: OTHER:MB001-004

Registered primary outcomes

Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 [Baseline to Week 28]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013562	Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Guja C, Diabetes therapy : research, treatment and education of diabetes and related disorders	2020	Other trial	PMID 32306296 DOI	cites ClinicalTrials.gov:NCT01652729; registry reference DERIVED:32306296
R0010641	Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Gadde KM, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28205322 DOI	cites ClinicalTrials.gov:NCT01652729; registry reference DERIVED:28205322